Zicam Extreme Congestion Relief — Class I drug recall D-155-2013
Terminated recall by Matrixx Initiatives Inc, reported 2013-02-13, distributed nationwide. Microbial Contamination of Non-Sterile Products: Product may be contaminated with Burkholderia cepacia.
| Recall number | D-155-2013 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Matrixx Initiatives Inc, Scottsdale, AZ, United States |
| Recall initiated | 2012-12-18 |
| Classified | 2013-02-07 |
| Reported by FDA | 2013-02-13 |
| Terminated | 2013-11-14 |
| Distributed | Nationwide (US) |
| Quantity | 46,752 bottles |
| Reason classes | microbial contamination, sterility |
| Pathogens | burkholderia |
| UPC / GTIN / UDI-DI | 00732216204100 |
| NDC | 62750-0005-10 |
| Lot numbers | 09/15, 2J23 |
Product
Zicam Extreme Congestion Relief (oxymetazoline HCl) nasal gel, 0.05%, 0.50 fl. oz. (15 mL) spray bottle, Developed and distributed by Zicam LLC, Scottsdale, Arizona 85255, a wholly owned subsidiary of Matrixx Initiatives Inc, NDC 62750-005-10, UPC 7 32216 20410 0.
Reason for recall
Microbial Contamination of Non-Sterile Products: Product may be contaminated with Burkholderia cepacia.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-155-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.